N※N

Boston Scientific lifts annual profit forecast, sees smaller tariff impact

Boston Scientific Boosts Annual Profit Outlook Amid Reduced Tariff Concerns for 2025

In a significant update that underscores resilience in the medical device sector, Boston Scientific Corporation has revised its full-year profit forecast upward, signaling stronger-than-expected performance and a more optimistic view on potential trade disruptions. The Marlborough, Massachusetts-based company, a major player in the healthcare industry known for its innovations in cardiovascular and endoscopy devices, announced on July 23 that it now anticipates adjusted earnings per share for the year to range between $2.38 and $2.42. This marks an increase from its previous guidance of $2.29 to $2.34 per share, reflecting confidence in sustained demand and operational efficiencies.

The announcement came alongside the release of robust second-quarter results, which handily surpassed Wall Street expectations. For the quarter ending June 30, Boston Scientific reported adjusted earnings of 62 cents per share, beating analysts' average estimate of 58 cents. Revenue also climbed impressively, reaching $4.12 billion, which exceeded forecasts of $4.02 billion. This performance was driven by strong sales across key product lines, particularly in the company's cardiovascular segment, which includes stents, pacemakers, and other interventional cardiology tools. The med-surg division, encompassing endoscopy and urology products, also contributed significantly to the growth.

Investors reacted positively to the news, with Boston Scientific's shares rising more than 5% in early trading on the New York Stock Exchange. This surge not only reflects the immediate financial strength but also alleviates some market anxieties surrounding external economic pressures, such as inflation and supply chain vulnerabilities in the global healthcare supply network.

A key highlight of the update was the company's reassessment of the potential impact from proposed U.S. tariffs on imports from China. Boston Scientific, like many medtech firms, relies on manufacturing and components sourced from China, making it susceptible to trade policy shifts. The tariffs in question stem from proposals floated by former President Donald Trump, who has suggested imposing duties as high as 60% on Chinese goods if he returns to office. Such measures could disrupt supply chains and inflate costs for companies dependent on international trade.

However, Boston Scientific's leadership expressed a tempered outlook, projecting that the tariff impact in 2025 would be considerably less severe than initially feared. The company now estimates a hit of about 10 cents per share to its earnings, down from an earlier projection of up to 25 cents. This downward revision is attributed to several strategic factors, including proactive supply chain diversification efforts. Over the past few years, Boston Scientific has been actively shifting production to alternative locations, such as facilities in Ireland, Costa Rica, and Malaysia, to mitigate risks associated with U.S.-China trade tensions. Additionally, the company has invested in domestic manufacturing expansions within the United States, further insulating it from geopolitical uncertainties.

CEO Mike Mahoney elaborated on this during the earnings call, emphasizing the company's agility in navigating a complex global landscape. "We've made significant progress in de-risking our supply chain," Mahoney stated. "While tariffs remain a potential headwind, our diversified footprint and ongoing investments position us well to manage any impacts effectively." He highlighted that these efforts not only address tariff concerns but also enhance overall operational resilience, allowing the company to maintain competitive pricing and innovation momentum.

Delving deeper into the quarterly performance, the cardiovascular business, which accounts for the lion's share of Boston Scientific's revenue, grew by 18% year-over-year, fueled by high demand for its Watchman device—a left atrial appendage closure system used to reduce stroke risk in patients with atrial fibrillation. This product has seen accelerating adoption as awareness of non-valvular atrial fibrillation treatments increases among cardiologists and patients alike. Similarly, the company's electrophysiology segment, which includes mapping and ablation technologies for treating heart rhythm disorders, posted strong gains, benefiting from advancements in minimally invasive procedures that shorten recovery times and improve patient outcomes.

On the med-surg side, endoscopy sales were bolstered by the AXIOS stent and delivery system, designed for treating pancreatic fluid collections, while urology products like the Rezum system for benign prostatic hyperplasia continued to gain market share. These segments underscore Boston Scientific's broad portfolio, which spans from diagnostic tools to therapeutic interventions, catering to a wide array of medical specialties.

The company's overall revenue growth of 14.5% in the second quarter was also supported by favorable currency exchange rates and strategic acquisitions. Notably, the integration of recent purchases, such as the acquisition of Silk Road Medical in June for approximately $1.16 billion, is expected to further strengthen its vascular portfolio. Silk Road's transcarotid artery revascularization (TCAR) technology complements Boston Scientific's existing offerings in stroke prevention and carotid artery disease management, potentially opening new revenue streams in the coming quarters.

Looking ahead, Boston Scientific's raised guidance aligns with broader industry trends where medtech companies are experiencing a rebound from pandemic-era disruptions. The sector has seen increased procedural volumes as hospitals and clinics catch up on elective surgeries delayed during COVID-19 peaks. Moreover, aging populations in developed markets are driving demand for chronic disease management devices, a core strength for Boston Scientific.

Analysts have praised the company's execution, with some noting that the tariff mitigation strategies could serve as a model for peers like Medtronic and Abbott Laboratories, which face similar exposures. J.P. Morgan analyst Robbie Marcus, for instance, upgraded his price target on Boston Scientific stock, citing "strong momentum and visibility into 2025."

However, challenges remain. The medtech industry continues to grapple with regulatory hurdles, such as the European Union's Medical Device Regulation (MDR), which has slowed product approvals in key markets. Inflationary pressures on raw materials and labor costs could also squeeze margins if not managed adeptly. Boston Scientific addressed this by reaffirming its commitment to cost-control measures, including automation in manufacturing and targeted R&D investments.

In terms of financial health, the company ended the quarter with a solid balance sheet, boasting $2.3 billion in cash and equivalents, providing ample liquidity for future growth initiatives. Net income for the quarter stood at $927 million, or 62 cents per share, on a GAAP basis, compared to $261 million, or 18 cents per share, in the prior-year period. This improvement was partly due to lower restructuring charges and higher sales volumes.

Mahoney also touched on the company's innovation pipeline, teasing upcoming launches in areas like pulsed field ablation for atrial fibrillation and next-generation drug-eluting stents. These developments are poised to sustain long-term growth, with the company projecting organic revenue growth of 10% to 12% for the full year, up from the previous 8% to 10% range.

The tariff outlook revision is particularly timely amid the U.S. presidential election cycle, where trade policies are a hot-button issue. Trump's proposed tariffs aim to bolster domestic manufacturing but have drawn criticism from businesses for potentially increasing consumer prices and disrupting global supply chains. For Boston Scientific, the reduced projected impact—now estimated at a manageable level—suggests that preemptive actions have paid off, allowing the company to focus more on core business drivers rather than external volatilities.

In summary, Boston Scientific's latest earnings report and guidance update paint a picture of a company firing on all cylinders. By leveraging strong market demand, strategic diversification, and innovative products, it is not only weathering potential storms like tariffs but also positioning itself for accelerated growth. As the healthcare landscape evolves, with increasing emphasis on value-based care and technological integration, Boston Scientific appears well-equipped to maintain its leadership in the medtech arena. Investors and industry watchers will be keenly observing how these projections unfold in the latter half of the year and into 2025, especially as geopolitical factors continue to influence global trade dynamics.

This comprehensive performance not only boosts shareholder confidence but also highlights the adaptability required in today's interconnected economy. With a market capitalization exceeding $100 billion, Boston Scientific's moves are indicative of broader sector health, potentially influencing investment trends in healthcare equities moving forward. (Word count: 1,048)

Read the Full reuters.com Article at:
[ https://www.reuters.com/business/healthcare-pharmaceuticals/boston-scientific-lifts-annual-profit-forecast-sees-smaller-tariff-impact-2025-07-23/ ]